<DOC>
	<DOCNO>NCT02554019</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy repeat intravenous infusion study drug BT063 patient Systemic Lupus Erythematosus ( SLE ) compare people receive placebo .</brief_summary>
	<brief_title>Proof-of-Concept Study With BT063 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Study 990 Phase IIa , proof-of-concept study BT063 subject SLE . This study divide 2 part . After Part I interim analysis perform . Each Part enrol 18 subject . Subjects randomly assign receive BT063 Placebo 8 time 12 week follow 4 month last dose .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Eligible male female subject , Age ≥ 18 ≤ 75 year Body mass index ≥ 18 ≤ 35 kg/m2 screen visit Diagnosed SLE ( define ≥ 4 11 American College Rheumatology ( ACR ) classification criterion SLE ) least 3 month screen Moderate severe SLE disease activity demonstrate SLEDAI2K total score ≥ 6 , include skin joint involvement CLASI Activity score ≥ 5 least 5 66/68 joint pain sign inflammation Positive antinuclear antibody ( ANA ) test screen No change concomitant medication SLE activity maintenance symptom control regard type medication dose level least 8 week prior baseline ( steroid NSAIDs/pain medication 2 week ) Normal electrocardiogram ( ECG ) Active , severe neuropsychiatric SLE define neuropsychiatric element score BILAG level A disease lupus nephritis Diagnosed psoriasis Presence history malignancy within previous 5 year Systemic antibiotic treatment within 2 week baseline visit A positive diagnosis viral hepatitis B hepatitis C Human immunodeficiency virus ( HIV ) test positive tuberculosis assess recent infection Herpes Zoster Herpes Simplex ( Type 1 Type 2 ) , EpsteinBarr virus ( EBV ) cytomegalovirus ( CMV ) infection reactivation screen Clinically significant hematologic abnormality attribute SLE : Haemoglobin &lt; 8 g/dL ; Platelets &lt; 50 E9/L ; Leucocytes &lt; 2.0 E9/L Active history inflammatory bowel disease ( include active history colitis ) Received following medication : Rituximab within last 48 week screen Belimumab within last 12 week screen IV immunoglobulin ( Ig ) within last 12 week screen Intramuscular ( IM ) intraarticular glucocorticosteroids within last 4 week screen IV cyclophosphamide within last 6 month screen IV glucocorticosteroids ( pulse therapy ) within last 6 month screen Pregnant nursing woman woman intend become pregnant Known intolerance immunoglobulin comparable substance ( e.g. , significant vaccination reaction ) Known intolerance protein human origin History clinically significant drug alcohol abuse within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SLE , Lupus</keyword>
	<keyword>IL10 , IL-10 , BT063 , BT-063</keyword>
</DOC>